Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 21, 2016; 22(3): 1311-1320
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1311
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1311
1st line regimen | 2nd line regimen | |
Japan[15] | PPI, amoxicillin 750 mg, clarithromycin 200 mg to 400 mg twice daily | PPI, amoxicillin 750 mg, metronidazole 250 mg twice daily |
Duration: 7 d | Duration: 7 d | |
Korea[14] | PPI, amoxicillin 1 g, clarithromycin 500 mg twice daily | PPI, bismuth 120 mg four times daily, tetracycline 500 mg four times daily, metronidazole 500 mg three times daily |
Duration: 7-14 d | Duration: 7-14 d | |
Europe[16] | PPI-clarithromycin containing triple therapy OR | Bismuth-containing quadruple therapy OR levofloxacin-containing triple |
Bismuth or non-bismuth containing quadruple1 | ||
Duration: 7-14 d | Duration: 10 d | |
China[13] | No preferential choice. Options include: (1)PPI, amoxicillin 1 g, clarithromycin 500 mg twice daily (2) PPI, amoxicillin 1 g, levofloxacin 200 mg twice daily (or levofloxacin 500 mg daily) (3) PPI, amoxicillin 1 g, furazolidone 100 mg twice daily (4) PPI, tetracycline 750 mg, metronidazole 400 mg twice daily (or metronidazole 400 mg three times per day) (5) PPI, bismuth 220 mg plus any of the two antibiotics above twice daily | |
Duration: 7-14 d |
Corpus | ||||
No atrophy (score 0) | Mild atrophy (score 1) | Moderate atrophy (score 2) | Severe atrophy (score 3) | |
Antrum (including incisura angularis) | ||||
No atrophy (score 0) | Stage 0 | Stage I | Stage II | Stage II |
Mild atrophy (score 1) | Stage I | Stage I | Stage II | Stage III |
Moderate atrophy (score 2) | Stage II | Stage II | Stage III | Stage IV |
Severe atrophy (score 3) | Stage III | Stage III | Stage IV | Stage IV |
Ref. | Intervention | Study design | Countries | Number of patients | Results |
Kong et al[38], 2014 | H. pylori eradication | Meta-analysis of 16 trials (including 1 RCT and 15 observational studies) | China, Japan, Italy and Columbia | 3432 | Antral IM: pooled WMD with 95%CI: 0.23 (0.18-0.29) |
Corpus IM: pooled WMD with 95%CI: -0.01 (-0.04-0.02) | |||||
Leung et al[42], 2006 | Rofecoxib for 24 mo | RCT (vs placebo) | China | 213 after H. pylori eradication | Antrum IM regression: 24.5% vs 26.9% in placebo |
Corpus IM regression 4.3% vs 2.2% in placebo | |||||
Wong et al[43], 2012 | Celecoxib for 24 mo | RCT (H. pylori eradication, celecoxib or both) | China | 1024 H. pylori positive | OR for regression of gastric lesions 1.72 (95%CI: 1.07-2.76) |
You et al[44], 2006 | Vitamins or Anti-oxidants | RCT (H. pylori eradication, vitamins or garlic supplements) | China | 3365 | Both vitamins and garlic supplements have no effect on gastric precancerous lesion |
- Citation: Liu KSH, Wong IOL, Leung WK. Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance. World J Gastroenterol 2016; 22(3): 1311-1320
- URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1311.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1311